{"analyses":[{"ciLowerLimit":"70.93","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"251.73","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Ratio of geometric means","paramValue":"133.62"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"41.8","value":"563"},{"groupId":"OG001","spread":"144.7","value":"752"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with normal renal function received carfilzomib 20 mg/m² IV on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles.","id":"OG000","title":"Normal Renal Function"},{"description":"Participants with ESRD received carfilzomib 20 mg/m² IV on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles.","id":"OG001","title":"End Stage Renal Disease"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK evaluable population for cycle 2, day 1. One participant was excluded due to samples taken from the infusion arm, distal to the infusion site.","reportingStatus":"POSTED","timeFrame":"Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.","title":"Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2","type":"PRIMARY","unitOfMeasure":"ng*h/mL"}